Decitabine Treatment Could Ameliorate Primary Iron-Overload in Myelodysplastic Syndrome Patients

REFERENCES

• Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009;361(19):1872–1885.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Della Porta MG, Laarakkers CM, Gallì A, Albertini R, Maffioli M, Ambaglio I, Travaglino E, Invernizzi R, Moratti R, Swinkels DW, Cazzola M. Erythroid activity, transfusion iron overload, and hepcidin levels in patient with myelodysplastic syndrome. Blood 2008;112(11):2676.
   Google Scholar
• Gattermann N, Rachmilewitz EA. Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol 2011;90(1):1–10.
   PubMed Web of Science ®Google Scholar
• Ambaglio I, Malcovati L, Papaemmanuil E, Laarakkers CM, Della Porta MG, Galli A, Da Vià MC, Bono E, Ubezio M, Travaglino E, Albertini R, Campbell PJ, Swinkels DW, Cazzola M.Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica 2013;98(3):420–423.
   Google Scholar
• Ning B, Liu G, Liu Y, Su X, Anderson GJZheng X, Chang Y, Guo M, Liu Y, Zhao Y, Nie G. 5-aza-2′-deoxycytidine activates iron uptake and heme biosynthesis by increasing c-Myc nuclear localization and binding to the E-boxes of transferrin receptor 1 (TfR1) and ferrochelatase (Fech) genes. J Biol Chem 2011;28:37196–37206.
   Web of Science ®Google Scholar
• Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med 2011;62:347–360.
   PubMed Web of Science ®Google Scholar
• Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, Campagna JA , Chung RTSchneyer AL, Woolf CJ, Andrews NC, Lin HY.Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006;38:531–539.
   PubMed Web of Science ®Google Scholar
• Babitt JL, Huang FW, Xia Y,Sidis Y, Andrews NC, Lin HY.Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 2007;117:1933–1939.
   PubMed Web of Science ®Google Scholar
• Maegdefrau U, Arndt S, Kivorski G, Hellerbrand C, Bosserhoff A-K. Downregulation of hemojuvelin prevents inhibitory effects of bone morphogenetic proteins on iron metabolism in hepatocellular carcinoma. Lab Invest 2011;91:1615–1623.
   PubMed Web of Science ®Google Scholar
• Brunning R, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I. Myelodysplastic syndromes. In World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissue, 4th edition, S Swerdlow, E Campo, NL Harris, et al. (eds.). Lyon, France: IARC Press, 2008, 88–103.
   Google Scholar
• Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G,Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J.International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89(6):2079–2088.
   PubMed Web of Science ®Google Scholar
• Cheson B, Greenberg P, Bennett J,Lowenberg B, Wijermans P, Nimer S, Pinto A, Berman M, de Witte T, Stone R, Mittelman M, Sanz G, Gore S, Schiffer C, Kantarjian H.Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419–425.
   PubMed Web of Science ®Google Scholar
• Armand P, Kim H, Rhodes J,Sainvil MM, Culter C, Ho VT, Koreth J, Alyea EP, Hearsey D, Neufeld EJ, Fleming MD, Steen H, Anderson D, Kwong RY, Soiffer RJ, Antin JH.Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant 2011;17(6): 852–860.
   PubMed Web of Science ®Google Scholar
• Ghoti H, Rachmilewitz EA, Simon-Lopez R,Gaber R, Katzir Z, Konen E, Kushnir T, Girelli D, Campostrini N, Fibach E, Goitein O.Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol 2012;89(1):87–93.
   PubMed Web of Science ®Google Scholar
• Saxonov S, Berg P, Brutlag DL. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci USA 2006;103: 1412–1417.
   PubMed Web of Science ®Google Scholar
• Pomraning KR, Smith KM, Freitag M. Genome-wide high throughput analysis of DNA methylation in eukaryotes. Methods 2009;47:142–150.
   PubMed Web of Science ®Google Scholar
• Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005;2(Suppl 1):S4–S11.
   PubMedGoogle Scholar
• Leone G, Teofili L, Voso MT, Lübbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002;87(12):1324–1341.
   PubMed Web of Science ®Google Scholar
• Santini V, Kantarjian HM, Issa J-P. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001;134(7):573–586.
   PubMed Web of Science ®Google Scholar
• Bernstein I, Byun HM, Mohrbacher A,Douer D, Gorospe G 3rd, Hergeseimer J, Groshen S, O'Connell C, Yang As.A phase I biological study of azacitidine (Vidaza™) to determine the optimal dose to inhibit DNA methylation. Epigenetics 2010;5(8):750–757.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Skrabanek L, Li Y,Jiemjit A, Fandy TE, Paietta E, Fernandez H, Tallman MS, Greally JM, Carraway H, Licht JD, Gore SD, Melnick A.MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009;114(16):3448–3458.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Della Porta MG, Cazzola M. Predicting Survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 2006;91:1588–1590.
   PubMed Web of Science ®Google Scholar
• Sanz G, Nomdedeu B, Such E, Bernal T, Belkaid M,Ardanaz MT, Marco V, Pedro C, Ramos F, Cañizo MC, Luño E, Cobo F, Carbonell F, Gomez V, Muñoz JA, Amigo ML, Bailen A, Bonanad S, Tormo M, Andreu R, Arrizabalaga B, Arilla MJ, Bueno J, Requena MJ, Bargay J, Sanchez J, Senent L, Arenillas L, Paz R, Xicoy L, Duarte R, Cervera J.Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 2008;112:640, ASH (Annual Meeting Abstracts).
   Web of Science ®Google Scholar
• Silvestri L, Pagani A, Fazi C, Gerardi G, Levi S,Arosio P, Camaschella C.Defective targeting of hemojuvelin to plasma membrane is a common pathogenetic mechanism in juvenile hemochromatosis. Blood 2007;109:4503–4510.
   PubMed Web of Science ®Google Scholar
• Rodriguez Martinez A, Niemela O, Parkkila S. Hepatic and extrahepatic expression of the new iron regulatory protein hemojuvelin. Haematologica. 2004;89:1441–1445.
   PubMedGoogle Scholar
• Niederkofler V, Salie R, Arber S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J Clin Invest 2005;115:2180–2186.
   PubMed Web of Science ®Google Scholar
• Babitt JL, Huang FW, Xia Y,Sidis Y, Andrews NC, Lin HY.Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 2007;117:1933–1939.
   PubMed Web of Science ®Google Scholar
• Huang FW, Pinkus JL, Pinkus GS,Fleming AD, Andrews NC.A mouse model of juvenile hemochromatosis. J Clin Invest 2005;115:2187–2191.
   PubMed Web of Science ®Google Scholar
• Niederkofler V, Salie R, Arber S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J Clin Invest 2005;115:2180–2186.
   PubMed Web of Science ®Google Scholar
• Babitt JL, Huang FW, Wrighting DM,Xia Y, Sidis Y, Samad TA, Campagna JA, Chung RT, Schneyer AL, Woolf CJ, Andrews NC, Lin HY.Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006;38:531–539.
   PubMed Web of Science ®Google Scholar
• Malyszko J, Malyszko JS, Levin-Iaina N, Koc-Zorawska E, Kozminski P, Mysliwiec M.Is hemojuvelin a possible new player in iron metabolism in hemodialysis patients? Int Urol Nephrol 2012;44(6):1805–1811.
   PubMed Web of Science ®Google Scholar
• Bartnikas TB, Fleming MD. Hemojuvelin is essential for transferrin-dependent and transferrin-independent hepcidin expression in mice. Haematologica 2012;97(2):189–192.
   PubMed Web of Science ®Google Scholar
• Zhang AS, Anderson SA, Meyers KR,Hernandez C, Eisenstein RS, Enns CA.Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin. J Biol Chem 2007;282:12547–12556.
   PubMed Web of Science ®Google Scholar